Billiontoone, Inc.’s Quiet Period Will End on December 16th (NASDAQ:BLLN)

Billiontoone’s (NASDAQ:BLLN) quiet period will expire on Tuesday, December 16th. Billiontoone had issued 4,551,100 shares in its initial public offering on November 6th. The total size of the offering was $273,066,000 based on an initial share price of $60.00. During the company’s quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analysts Set New Price Targets

A number of research analysts recently issued reports on BLLN shares. William Blair began coverage on Billiontoone in a research report on Monday, December 1st. They set an “outperform” rating for the company. Zacks Research upgraded Billiontoone to a “hold” rating in a research note on Tuesday, December 2nd. Wall Street Zen upgraded shares of Billiontoone to a “hold” rating in a research report on Saturday, November 15th. BTIG Research reaffirmed a “buy” rating and issued a $160.00 price objective on shares of Billiontoone in a report on Wednesday. Finally, Wells Fargo & Company began coverage on shares of Billiontoone in a research report on Monday, December 1st. They issued an “equal weight” rating and a $110.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $137.83.

Billiontoone Stock Performance

Shares of Billiontoone stock opened at $101.99 on Friday. Billiontoone has a 1-year low of $88.00 and a 1-year high of $138.70.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Tuesday, December 9th. The company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.06). The firm had revenue of $83.52 million during the quarter, compared to the consensus estimate of $82.86 million.

Billiontoone Company Profile

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.